Balyasny Asset Management’s Kailera Therapeutics KLRA Stock Holding History

Balyasny Asset Management’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.41M	Buy	+154,838	New	+$3.4M	﹤0.01%	1559

Other funds holding KLRA

BCI

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Balyasny Asset Management's KLRA Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 154,838 shares worth $3.41M. The stake represents ﹤0.01% of the portfolio and ranks #1559 among its holdings.

99 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Balyasny Asset Management held 154,838 shares of Kailera Therapeutics worth $3.41M as of Q2 2026.
Kailera Therapeutics was a new Balyasny Asset Management position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1559 holding.
99 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.